A Review of the Literature on the Selegiline Transdermal System

Abstract

The selegiline transdermal system provides several advantages compared to orally administered MAOIs, including minimal interaction with dietary tyramine and prolonged exposure to the parent compound, while offering a favorable side effect profile. As a result, treatment at the lowest effective dose of 6 mg/24 hours can be administered without the need for dietary modifications.

Women’s sexual dysfunction associated with psychiatric disorders and their treatment

“…Table 2 indicates presumed mechanism of interference with sexual response with different classes of antidepressants as well as approximate risk of medication-associated dysfunction. 72–83…”

“…73 dA recent formulation of transdermal selegiline is reported to be comparable to placebo in terms of sexual side effects. 74 eClayton et al 75 fMontejo et al 76 gPereira et al 77 hBoyarsky and Hirshfeld. 78 iBaldwin.…”

“…dA recent formulation of transdermal selegiline is reported to be comparable to placebo in terms of sexual side effects. 74 …”

Options when anti-depressants cannot be used in conventional ways. Clinical case and review of literature

“…By this route, selegiline gets directly absorbed into the systemic circulation, bypassing the gastrointestinal tract and first-pass metabolism. The patch is applied once daily for the treatment of major depressive disorder [15]. It comes in three different doses and patch sizes: 6 mg/24 h patch, 9 mg/24 h patch, and 12 mg/ 24 h patch.…”

“…As the transdermal delivery system avoids gastrointestinal tract exposure it minimizes food-drug interaction risks associated with MAO inhibition in the gut and thereby enhances the safety of the selegiline given at standard doses. Thus, if an alternate route is needed then the selegiline transdermal system provides psychiatrists with a potentially helpful treatment option, which is FDA approved and commercially available [8,15].…”